Small Molecules Blog
Opportunities and Perspectives on the Design and Synthesis of PROTAC® Degraders
Somatic Instability and Huntington's Disease
Development of a KRAS-Targeting PROTAC
In this question-and-answer session, Michael Bond (Yale University) talks to our Senior Product Specialist, Alex Moloney PhD, about the development of LC 2, a KRAS G12C-targeting PROTAC® which is now available from Tocris.
Regenerative Medicine - From Bench to Clinic
SARS-CoV-2: An Update on Key Targets, Trends and Discoveries
Existing Drugs Targeting SARS-CoV-2 and Coronaviruses
All Tocris products mentioned in this blog post are for biomedical research use only. They are not intended for human or veterinary use.
